Vanda Pharmaceuticals Inc (VNDA) Q1 2026 Earnings Call Transcript

Why It Matters

The strong Fanapt momentum and new product launches expand Vanda’s revenue base, but rising cash outflows and uncertain uptake of Nirius pose execution risks for investors. Consequently, the raised guidance reflects both growth potential and heightened financial pressure.

Key Takeaways

• Fanapt sales up 26% YoY, prescriptions +32%.
• Hetlioz sales down 24% YoY due to generics.
• Nirius launched direct-to-consumer, $85 cash-pay price.
• Dysanti approved for bipolar I and schizophrenia.
• 2026 revenue guidance raised to $240‑$290 million.

Pulse Analysis

Vanda’s Q1 performance underscores the resilience of its core antipsychotic franchise. Fanapt’s 26% year‑over‑year sales lift, driven by expanded bipolar disorder labeling and an enlarged sales force, translated into a 32% jump in total prescriptions and a 76% surge in new‑to‑brand starts. This momentum helped offset the inevitable erosion of Hetlioz, which continues to lose market share as generic competitors gain traction, and illustrates the company’s ability to leverage brand‑specific strategies in a crowded atypical‑antipsychotic market.

The launch of Nirius marks a strategic pivot toward direct‑to‑consumer distribution, bypassing traditional pharmacy channels and offering a 65% cash‑pay discount at $85 per capsule. As the first new prescription therapy for motion‑induced vomiting in four decades, Nirius opens a niche revenue stream while testing a novel pricing model that could be replicated across Vanda’s pipeline. Simultaneously, the FDA approval of Dysanti expands the company’s psychiatric portfolio into bipolar I disorder and schizophrenia, adding a product protected by data exclusivity through 2031 and patents through 2044, thereby strengthening long‑term revenue diversification.

Financially, Vanda raised its 2026 revenue guidance to $240‑$290 million, reflecting confidence in Nirius and Dysanti contributions but also acknowledging heightened cash burn, with Q1 cash balances falling to $202 million after a $61 million decline. Elevated SG&A spending on commercial expansion and a one‑time milestone payment to Eli Lilly signal aggressive growth tactics, yet the company cautions that cash consumption may outpace 2025 levels. Investors must weigh the upside of expanding product lines against the volatility of generic pressure and the uncertain market uptake of the cash‑pay model, making Vanda’s outlook a blend of promising growth and fiscal caution.